Sinsin Pharmaceutical Co., Ltd (KOSDAQ:002800)
South Korea · Delayed Price · Currency is KRW 5,930.00
-100.00 (-1.66%)
At close: Feb 13, 2026
Sinsin Pharmaceutical Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Operating Revenue | 110,285 | 106,388 | 102,586 | 91,926 | 74,008 | 67,129 |
Other Revenue | -0 | -0 | -0 | - | -0 | - |
| 110,285 | 106,388 | 102,586 | 91,926 | 74,008 | 67,129 | |
Revenue Growth (YoY) | 4.31% | 3.71% | 11.60% | 24.21% | 10.25% | -1.07% |
Cost of Revenue | 70,125 | 70,278 | 69,274 | 61,706 | 52,318 | 48,708 |
Gross Profit | 40,160 | 36,110 | 33,312 | 30,220 | 21,689 | 18,421 |
Selling, General & Admin | 29,490 | 27,385 | 25,726 | 23,770 | 21,277 | 20,967 |
Research & Development | 700.62 | 474.5 | 488.03 | 89.9 | 709.07 | 785.21 |
Amortization of Goodwill & Intangibles | 17.15 | 15.79 | 14.09 | 9.43 | - | 1.95 |
Other Operating Expenses | 263.31 | 240.35 | 220.94 | 228.42 | 220.21 | 276.09 |
Operating Expenses | 31,555 | 29,220 | 27,308 | 24,794 | 23,032 | 22,591 |
Operating Income | 8,605 | 6,890 | 6,004 | 5,426 | -1,343 | -4,170 |
Interest Expense | -1,704 | -1,960 | -1,937 | -1,481 | -963.24 | -893.62 |
Interest & Investment Income | 36.64 | 37.83 | 40.34 | 8.3 | 2 | 15.55 |
Currency Exchange Gain (Loss) | 174.46 | 404.45 | 19.14 | 277.35 | 242.67 | -201.51 |
Other Non Operating Income (Expenses) | 98.08 | 84.44 | -131.88 | -222.32 | 331.37 | 398.98 |
EBT Excluding Unusual Items | 7,209 | 5,457 | 3,995 | 4,009 | -1,730 | -4,850 |
Gain (Loss) on Sale of Investments | -323.41 | -323.41 | - | - | - | - |
Gain (Loss) on Sale of Assets | 43.35 | 7 | -0 | 38.55 | 0.73 | 4,581 |
Asset Writedown | - | - | - | - | -18.16 | - |
Pretax Income | 6,929 | 5,141 | 3,995 | 4,047 | -1,747 | -269.32 |
Income Tax Expense | 430.7 | 329.15 | -651.57 | -308.12 | -297.73 | -470.61 |
Earnings From Continuing Operations | 6,499 | 4,811 | 4,646 | 4,355 | -1,449 | 201.29 |
Minority Interest in Earnings | 2.54 | 77.05 | 33.77 | 59.32 | -26.47 | 161.37 |
Net Income | 6,501 | 4,888 | 4,680 | 4,415 | -1,476 | 362.66 |
Net Income to Common | 6,501 | 4,888 | 4,680 | 4,415 | -1,476 | 362.66 |
Net Income Growth | 63.18% | 4.46% | 6.01% | - | - | -83.03% |
Shares Outstanding (Basic) | 15 | 15 | 15 | 15 | 15 | 15 |
Shares Outstanding (Diluted) | 15 | 15 | 15 | 15 | 15 | 15 |
Shares Change (YoY) | 0.13% | - | - | - | - | - |
EPS (Basic) | 428.26 | 322.24 | 308.49 | 291.00 | -97.29 | 23.91 |
EPS (Diluted) | 428.26 | 322.24 | 308.49 | 291.00 | -97.29 | 23.91 |
EPS Growth | 63.20% | 4.46% | 6.01% | - | - | -83.03% |
Free Cash Flow | 2,527 | 4,439 | -1,081 | 4,553 | -2,659 | -10,104 |
Free Cash Flow Per Share | 166.48 | 292.60 | -71.27 | 300.15 | -175.28 | -666.04 |
Dividend Per Share | 60.000 | 60.000 | - | - | - | - |
Gross Margin | 36.41% | 33.94% | 32.47% | 32.87% | 29.31% | 27.44% |
Operating Margin | 7.80% | 6.48% | 5.85% | 5.90% | -1.81% | -6.21% |
Profit Margin | 5.90% | 4.59% | 4.56% | 4.80% | -1.99% | 0.54% |
Free Cash Flow Margin | 2.29% | 4.17% | -1.05% | 4.95% | -3.59% | -15.05% |
EBITDA | 12,835 | 11,150 | 9,941 | 9,184 | 2,329 | -1,586 |
EBITDA Margin | 11.64% | 10.48% | 9.69% | 9.99% | 3.15% | -2.36% |
D&A For EBITDA | 4,230 | 4,260 | 3,937 | 3,758 | 3,672 | 2,584 |
EBIT | 8,605 | 6,890 | 6,004 | 5,426 | -1,343 | -4,170 |
EBIT Margin | 7.80% | 6.48% | 5.85% | 5.90% | -1.81% | -6.21% |
Effective Tax Rate | 6.22% | 6.40% | - | - | - | - |
Advertising Expenses | - | 4,207 | 4,340 | 4,188 | 3,417 | 3,267 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.